Moody's rating threat to Pfizer's Boots bid

Moody's Investors Service warned yesterday it could strip Pfizer of its top-notch credit rating. The move could force the US pharmaceuticals giant to pay more if it turns to the debt markets to finance a bid for Boots Healthcare International.

Moody's placed Pfizer's triple-A rating on review for downgrade after the US giant was forced to suspend sales of its Bextra drug and withdraw its Celebrex drug.

WSJ Logo
The Worst Performer in Billionaires’ Portfolios? Trophy Art.External link

The Worst Performer in Billionaires’ Portfolios? Trophy Art.